Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: A systematic review and meta-analysis
Open Access
- 10 September 2024
- journal article
- review article
- Published by Elsevier in Taiwanese Journal of Obstetrics and Gynecology
- Vol. 63 (5) , 601-609
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancerEuropean Journal of Cancer, 2023
- Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trialEuropean Journal of Cancer, 2022
- Cancer of the ovary, fallopian tube, and peritoneum: 2021 updateInternational Journal of Gynecology & Obstetrics, 2021
- SEOM clinical guideline in ovarian cancer (2020)Clinical and Translational Oncology, 2021
- Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trialsCritical Reviews in Oncology/Hematology, 2019
- Ovarian cancer relapse: From the latest scientific evidence to the best practiceCritical Reviews in Oncology/Hematology, 2019
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2017
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trialThe Lancet Oncology, 2017
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trialThe Lancet Oncology, 2017
- Inherited Mutations in Women With Ovarian CarcinomaJAMA Oncology, 2016